- 學位論文
Rosiglitazone 透過 ERK-1/-2 信息傳遞路徑誘導腎臟環間膜細胞之分化
ERK-1/-2 Dependent Induction of Mesangial Cell Differentiation by Rosiglitazone
摘要
Rosiglitazone是一種peroxisome proliferator-activated receptor-gamma (PPAR-g agonist，在第二型糖尿病的實驗模式中被認為能夠減少 mesangium 的過度增生。本研究中發現，在大鼠腎臟環間膜細胞中給予PPAR-g agonist時，會調控大鼠腎臟環間膜細胞增生。當以rosiglitazone刺激大鼠腎臟環間膜細胞時，發現會造成活細胞數目與DNA合成的減少，並使得CDK 抑制劑--p21cip1的表現增加，進而造成細胞生長停滯。此外，rosiglitazone 也會增加大鼠腎臟環間膜細胞PDK-1、protein kinase B/Akt (PKB/Akt) Serine473 磷酸化與 Akt kinase的活性。而這些反應會被phosphatidylinositol 3-kinase (PI3-K)的抑制劑--LY294002 與 wortmannin 所抑制。而rosiglitazone 會使腎臟環間膜細胞分化的指標-- smooth muscle a-actin (SMA) 的表現增加。由於LY294002 與 wortmannin 並無法抑制 SMA 的表現，所以SMA 表現可能不是經由PI3-K 的信息傳遞路徑而來的。但是SMA 表現可以被protein tyrosine kinase的抑制劑--genistein 與 MEK 的抑制劑--PD98059所抑制。因此，推測 SMA 表現可能是透過protein tyrosine kinase-MEK-mitogen-activated protein kinase 的信息傳遞路徑來調控大鼠腎臟環間膜細胞的分化。這些結果證明了PPAR-g 透過 Erk 的傳遞路徑，扮演了調控腎臟環間膜細胞的分化的機制。
並列摘要
Rosiglitazone is a peroxisome proliferator-activated receptor-gamma (PPAR-g) agonist that has been shown to halt mesangium expansion in experimental models of type 2 diabetes mellitus. In the present study, rat mesangial cells were treated with rosiglitazone and its molecular mechanisms coupling growth arrest were examined. Treatment of rat mesangial cells with rosiglitazone resulted in reduction of viable cells and inhibition of [3H] thymidine incorporation. Treatment with rosiglitazone increased the expression of CDK inhibitor, p21CIP-1, which was associated with cell cycle arrest. Rosiglitazone increased PDK-1 and protein kinase B/Akt (PKB/Akt) Serine473 phosphorylation and Akt kinase activity in rat mesangial cells, and these responses were inhibited with the pharmacological inhibitor of phosphatidylinositol 3-kinase (PI3-K), LY294002 or wortmannin. Rosiglitazone increased the expression of smooth muscle a-actin (SMA), a differentiation marker for mesangial cells. LY294002 or wortmannin pretreated cells failed to blocked SMA expression suggesting SMA expression is not mediated through PI3-K dependent pathway. The expression of SMA was inhibited by genistein (a protein tyrosine kinase inhibitor), by PD98059 (a MEK inhibitor), suggesting protein tyrosine kinase-MEK-mitogen-activated protein kinase pathway mediates the differentiation of renal glomerular mesangial cells. These data demonstrate a role for PPAR-g in mediating a molecular mechanism coupling growth arrest and mesangial cell differentiation.